Wall Street Futures Slip as Oracle Earnings Miss Reignites AI Spending Concerns 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
Hong Kong Cuts Base Rate as HKMA Follows U.S. Federal Reserve Move 
ADB Approves $400 Million Loan to Boost Ease of Doing Business in the Philippines 
Gulf Sovereign Funds Unite in Paramount–Skydance Bid for Warner Bros Discovery 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Oil Prices Rebound in Asia as Venezuela Sanctions Risks Offset Ukraine Peace Hopes 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
Ireland Limits Planned Trade Ban on Israeli Settlements to Goods Only 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
U.S. Dollar Slides for Third Straight Week as Rate Cut Expectations Boost Euro and Pound 
Johnson & Johnson may be divided soon as there are plans to split it to become two separate companies. With the division, one will operate the pharmaceutical business while the other will be for the consumer products.
Johnson & Johnson revealed its plans to split up its consumer products and medical device operations late last week. It said it would be forming two publicly traded companies, and this news reportedly triggered an increase in the company’s shares after the figures went higher in premarket trading.
The move will separate J&J’s household products unit that makes leading brands such as Neutrogena, Aveeno, and Listerine, from its unit that makes and sells medical devices like AI and robotics and prescription drugs, including the COVID-19 vaccine.
The separation process is expected to be completed within 18 to 24 months. Based on the reports, the medical device unit will be retaining the Johnson & Johnson brand name, and the incoming chief executive officer, Joaquin Duato, will be leading this newly-formed company.
CNBC reported that for the consumer side of the business, outgoing CEO, Alex Gorsky, said they have not decided on its name yet.
“Following a comprehensive review, the board and management team believe that the planned separation of the consumer health business is the best way to accelerate our efforts to serve patients, consumers, and healthcare professionals, create opportunities for our talented global team, drive profitable growth,” Gorsky said in a statement regarding the split of the firm. “Most importantly – improve healthcare outcomes for people around the world.”
He added that the decision to separate the company into two was approved by the board after discussions that have been going on for some time already. They concluded it was a good step to take because they think it would bring numerous opportunities to stakeholders.
As per Los Angeles Times, the executives of Johnson & Johnson told analysts that the split of the company would make each business more adept in adapting to its respective markets. Gorsky stated the division will also address segments that “have evolved as fundamentally different businesses.” Meanwhile, Duato is set to replace Gorsky as CEO in January 2022.
